1,045
Participants
Start Date
April 7, 2022
Primary Completion Date
October 7, 2028
Study Completion Date
December 7, 2028
blood tests
"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
RECRUITING
University Hospital of Angers, Angers
NOT_YET_RECRUITING
Avicenne Hospital (Greater Paris University Hospitals), Bobigny
RECRUITING
University Hospital of Dijon, Dijon
RECRUITING
Departemental Hospital Center of Vendée, La Roche-sur-Yon
ACTIVE_NOT_RECRUITING
University Hospital of Grenoble, La Tronche
ACTIVE_NOT_RECRUITING
University Hospital of Lille, Lille
ACTIVE_NOT_RECRUITING
University Hospital of Limoges, Limoges
RECRUITING
La Croix Rousse Hospital, Lyon
RECRUITING
University Hospital of Montpellier, Montpellier
ACTIVE_NOT_RECRUITING
University Hospital of Nantes, Nantes
NOT_YET_RECRUITING
La Pitié Salpétrière Hospital (Greater Paris University Hospitals), Paris
ACTIVE_NOT_RECRUITING
Saint-Antoine Hospital (Greater Paris University Hospitals), Paris
ACTIVE_NOT_RECRUITING
University Hospital of Bordeaux, Pessac
ACTIVE_NOT_RECRUITING
University Hospital of Rennes, Rennes
ACTIVE_NOT_RECRUITING
University Hospital of Tours, Tours
University Hospital, Angers
OTHER_GOV